Pembrolizumab 联合 Folfirinox 治疗 MSI-H 晚期胰腺腺癌。

Q3 Medicine

European journal of case reports in internal medicine Pub Date : 2024-09-24 eCollection Date: 2024-01-01 DOI:10.12890/2024_004767

Ashmin Singh, Nairuti Sanghavi, Vandana Bandari, Iftekhar Khan, Abeer Alfaraj

{"title":"Pembrolizumab 联合 Folfirinox 治疗 MSI-H 晚期胰腺腺癌。","authors":"Ashmin Singh, Nairuti Sanghavi, Vandana Bandari, Iftekhar Khan, Abeer Alfaraj","doi":"10.12890/2024_004767","DOIUrl":null,"url":null,"abstract":"Pancreatic cancer is one of the four most common causes of cancer-related death in the United States. Our patient had metastatic pancreatic cancer with a high tumour burden. He was trialled on an unconventional treatment of combination immunotherapy and chemotherapy. It resulted in decreased cancer burden and decreased FDG activity on a PET scan. Further studies are needed for standard pancreatic cancer treatment.Learning points: Very few patients survive pancreatic cancer, especially metastatic disease. Our patient is doing very well after a few years.There is little evidence for concurrent use of chemotherapy and immunotherapy. Our patient received it and has had no new lesions, and there has been an improvement on imaging.","PeriodicalId":11908,"journal":{"name":"European journal of case reports in internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451846/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pembrolizumab in Combination with Folfirinox for Treatment of Advanced Pancreatic Adenocarcinoma With MSI-H.\",\"authors\":\"Ashmin Singh, Nairuti Sanghavi, Vandana Bandari, Iftekhar Khan, Abeer Alfaraj\",\"doi\":\"10.12890/2024_004767\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pancreatic cancer is one of the four most common causes of cancer-related death in the United States. Our patient had metastatic pancreatic cancer with a high tumour burden. He was trialled on an unconventional treatment of combination immunotherapy and chemotherapy. It resulted in decreased cancer burden and decreased FDG activity on a PET scan. Further studies are needed for standard pancreatic cancer treatment.Learning points: Very few patients survive pancreatic cancer, especially metastatic disease. Our patient is doing very well after a few years.There is little evidence for concurrent use of chemotherapy and immunotherapy. Our patient received it and has had no new lesions, and there has been an improvement on imaging.\",\"PeriodicalId\":11908,\"journal\":{\"name\":\"European journal of case reports in internal medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451846/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of case reports in internal medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12890/2024_004767\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of case reports in internal medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12890/2024_004767","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

胰腺癌是美国最常见的四大癌症致死原因之一。我们的病人患有转移性胰腺癌，肿瘤负担很重。他接受了免疫疗法和化疗相结合的非常规治疗。结果癌症负担减轻，正电子发射计算机断层扫描的 FDG 活性降低。标准的胰腺癌治疗还需要进一步研究：学习要点：胰腺癌，尤其是转移性胰腺癌患者的生存率非常低。我们的病人在几年后情况非常好。我们的病人接受了化疗，没有出现新的病灶，影像学也有所改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pembrolizumab in Combination with Folfirinox for Treatment of Advanced Pancreatic Adenocarcinoma With MSI-H.

Pancreatic cancer is one of the four most common causes of cancer-related death in the United States. Our patient had metastatic pancreatic cancer with a high tumour burden. He was trialled on an unconventional treatment of combination immunotherapy and chemotherapy. It resulted in decreased cancer burden and decreased FDG activity on a PET scan. Further studies are needed for standard pancreatic cancer treatment.

Learning points: Very few patients survive pancreatic cancer, especially metastatic disease. Our patient is doing very well after a few years.There is little evidence for concurrent use of chemotherapy and immunotherapy. Our patient received it and has had no new lesions, and there has been an improvement on imaging.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European journal of case reports in internal medicine

CiteScore

2.10

自引率

0.00%

发文量

166

审稿时长

8 weeks

期刊介绍： The European Journal of Case Reports in Internal Medicine is an official journal of the European Federation of Internal Medicine (EFIM), representing 35 national societies from 33 European countries. The Journal''s mission is to promote the best medical practice and innovation in the field of acute and general medicine. It also provides a forum for internal medicine doctors where they can share new approaches with the aim of improving diagnostic and clinical skills in this field. EJCRIM welcomes high-quality case reports describing unusual or complex cases that an internist may encounter in everyday practice. The cases should either demonstrate the appropriateness of a diagnostic/therapeutic approach, describe a new procedure or maneuver, or show unusual manifestations of a disease or unexpected reactions. The Journal only accepts and publishes those case reports whose learning points provide new insight and/or contribute to advancing medical knowledge both in terms of diagnostics and therapeutic approaches. Case reports of medical errors, therefore, are also welcome as long as they provide innovative measures on how to prevent them in the current practice (Instructive Errors). The Journal may also consider brief and reasoned reports on issues relevant to the practice of Internal Medicine, as well as Abstracts submitted to the scientific meetings of acknowledged medical societies.